NASDAQ:ADAP - Adaptimmune Therapeutics Stock Price, Forecast & News

Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP."

Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) issued its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.03. The biotechnology company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $7 million. View Adaptimmune Therapeutics' Earnings History.

Adaptimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Adaptimmune Therapeutics.

7 analysts have issued twelve-month target prices for Adaptimmune Therapeutics' stock. Their forecasts range from $4.15 to $8.00. On average, they anticipate Adaptimmune Therapeutics' share price to reach $6.03 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Adaptimmune Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adaptimmune Therapeutics.

Press coverage about ADAP stock has trended somewhat negative on Monday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Adaptimmune Therapeutics.

Adaptimmune Therapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,530,000 shares, a decrease of 35.2% from the December 31st total of 2,360,000 shares. Based on an average daily volume of 1,590,000 shares, the short-interest ratio is currently 1.0 days. Approximately 1.7% of the shares of the company are sold short. View Adaptimmune Therapeutics' Current Options Chain.

Some companies that are related to Adaptimmune Therapeutics include Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Coherus Biosciences (CHRS), Orchard Therapeutics (ORTX), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), NanoString Technologies (NSTG), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Vericel (VCEL) and Proteon Therapeutics (PRTO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Second Sight Medical Products (EYES), Brainstorm Cell Therapeutics (BCLI), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Chipotle Mexican Grill (CMG) and Micron Technology (MU).

(ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager.

Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADAP stock can currently be purchased for approximately $3.68.

Adaptimmune Therapeutics has a market capitalization of $385.26 million and generates $59.51 million in revenue each year. The biotechnology company earns $-95,510,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe.View Additional Information About Adaptimmune Therapeutics.

The official website for Adaptimmune Therapeutics is http://www.adaptimmune.com/.

Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected]